Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Hypoxia-induced Nur77 activates PI3K/Akt signaling via suppression of Dicer/let-7i-5p to induce epithelial-to-mesenchymal transition.

Tytuł:
Hypoxia-induced Nur77 activates PI3K/Akt signaling via suppression of Dicer/let-7i-5p to induce epithelial-to-mesenchymal transition.
Autorzy:
Shi Z; School of Biological Sciences, University of Hong Kong, Pokfulam Road, Hong Kong.
To SKY; School of Biological Sciences, University of Hong Kong, Pokfulam Road, Hong Kong.
Zhang S; State Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen, China.
Deng S; School of Biological Sciences, University of Hong Kong, Pokfulam Road, Hong Kong.
Artemenko M; School of Biological Sciences, University of Hong Kong, Pokfulam Road, Hong Kong.
Zhang M; State Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen, China.
Tang J; State Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen, China.
Zeng JZ; State Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen, China.
Wong AST; School of Biological Sciences, University of Hong Kong, Pokfulam Road, Hong Kong.
Źródło:
Theranostics [Theranostics] 2021 Jan 19; Vol. 11 (7), pp. 3376-3391. Date of Electronic Publication: 2021 Jan 19 (Print Publication: 2021).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: Wyoming, N.S.W. : Ivyspring International Publisher, 2011-
MeSH Terms:
Adenocarcinoma/*genetics
Class I Phosphatidylinositol 3-Kinases/*genetics
Colorectal Neoplasms/*genetics
DEAD-box RNA Helicases/*genetics
Hypoxia/*genetics
Liver Neoplasms/*genetics
MicroRNAs/*genetics
Nuclear Receptor Subfamily 4, Group A, Member 1/*genetics
Proto-Oncogene Proteins c-akt/*genetics
Ribonuclease III/*genetics
Adenocarcinoma/metabolism ; Adenocarcinoma/mortality ; Adenocarcinoma/secondary ; Animals ; Carcinogenesis/genetics ; Carcinogenesis/metabolism ; Carcinogenesis/pathology ; Cell Line, Tumor ; Cell Movement ; Cell Proliferation ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/mortality ; Colorectal Neoplasms/pathology ; DEAD-box RNA Helicases/metabolism ; Epithelial-Mesenchymal Transition/genetics ; Gene Expression Regulation, Neoplastic ; Humans ; Hypoxia/metabolism ; Hypoxia/mortality ; Hypoxia/pathology ; Liver Neoplasms/metabolism ; Liver Neoplasms/mortality ; Liver Neoplasms/secondary ; Mice ; Mice, Nude ; MicroRNAs/metabolism ; Neoplastic Stem Cells/metabolism ; Neoplastic Stem Cells/pathology ; Nuclear Receptor Subfamily 4, Group A, Member 1/antagonists & inhibitors ; Nuclear Receptor Subfamily 4, Group A, Member 1/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; Ribonuclease III/metabolism ; Signal Transduction ; Survival Analysis ; Transcription Factors/genetics ; Transcription Factors/metabolism ; Tumor Burden ; Tumor Suppressor Proteins/genetics ; Tumor Suppressor Proteins/metabolism ; Xenograft Model Antitumor Assays
References:
Carcinogenesis. 2014 Nov;35(11):2474-84. (PMID: 25064356)
J Natl Cancer Inst. 2015 Feb 06;107(3):. (PMID: 25663689)
PLoS Biol. 2004 Nov;2(11):e363. (PMID: 15502875)
Cancer Res. 1999 Nov 15;59(22):5830-5. (PMID: 10582706)
N Engl J Med. 2008 Dec 18;359(25):2641-50. (PMID: 19092150)
Nat Commun. 2014 Mar 03;5:3388. (PMID: 24584437)
EMBO J. 2006 Dec 13;25(24):5703-15. (PMID: 17139261)
Nucleic Acids Res. 2008 Jan;36(Database issue):D154-8. (PMID: 17991681)
Theranostics. 2013 Nov 29;3(12):930-42. (PMID: 24396504)
PLoS One. 2016 Feb 03;11(2):e0148433. (PMID: 26840408)
Ann Med. 2014 Sep;46(6):372-83. (PMID: 24897931)
Nature. 2012 Jul 18;487(7407):330-7. (PMID: 22810696)
Steroids. 2015 Mar;95:1-6. (PMID: 25555471)
Oncotarget. 2017 Dec 8;8(69):113977-113986. (PMID: 29371962)
Expert Opin Ther Targets. 2012 Jun;16(6):573-85. (PMID: 22537097)
J Biol Chem. 2004 Dec 17;279(51):53365-73. (PMID: 15385570)
FASEB J. 2011 Jan;25(1):192-205. (PMID: 20847229)
PLoS One. 2014 Sep 30;9(9):e109047. (PMID: 25269081)
Cancer Sci. 2005 Feb;96(2):111-5. (PMID: 15723655)
Cell. 2001 Dec 28;107(7):823-6. (PMID: 11779458)
World J Gastroenterol. 2012 Jul 28;18(28):3745-51. (PMID: 22851869)
Theranostics. 2013 Nov 30;3(12):943-52. (PMID: 24396505)
Nat Rev Genet. 2010 Sep;11(9):597-610. (PMID: 20661255)
Br J Cancer. 2014 Feb 18;110(4):935-45. (PMID: 24423919)
J Biol Chem. 2014 Jan 3;289(1):122-32. (PMID: 24220032)
Oncogene. 2014 Jul 24;33(30):4003-15. (PMID: 24096488)
Sci Rep. 2017 Jul 25;7(1):6396. (PMID: 28743867)
PLoS One. 2013 Sep 16;8(9):e74250. (PMID: 24066126)
Curr Oncol. 2010 Feb;17(1):70-80. (PMID: 20179807)
Crit Rev Oncol Hematol. 2015 Apr;94(1):18-30. (PMID: 25591826)
Hypoxia (Auckl). 2015 Dec 11;3:83-92. (PMID: 27774485)
Nat Rev Dis Primers. 2015 Nov 05;1:15065. (PMID: 27189416)
Oncogene. 2010 Aug 26;29(34):4741-51. (PMID: 20531305)
Nat Commun. 2014 Oct 29;5:5203. (PMID: 25351418)
Cancer Res. 2004 Jan 1;64(1):35-9. (PMID: 14729605)
J Clin Pathol. 2018 Feb;71(2):110-116. (PMID: 28942428)
Nat Commun. 2014 Oct 29;5:5202. (PMID: 25351346)
Br J Radiol. 2014 Mar;87(1035):20130676. (PMID: 24588669)
Microvasc Res. 2019 Mar;122:22-33. (PMID: 30391133)
Contributed Indexing:
Keywords: EMT; Nur77; PI3K/Akt; colorectal cancer; hypoxia; microRNA biogenesis
Substance Nomenclature:
0 (MicroRNAs)
0 (NR4A1 protein, human)
0 (Nuclear Receptor Subfamily 4, Group A, Member 1)
0 (TP63 protein, human)
0 (Transcription Factors)
0 (Tumor Suppressor Proteins)
0 (mirnlet7 microRNA, human)
EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
EC 2.7.1.137 (PIK3CA protein, human)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
EC 3.1.26.3 (DICER1 protein, human)
EC 3.1.26.3 (Ribonuclease III)
EC 3.6.4.13 (DEAD-box RNA Helicases)
Entry Date(s):
Date Created: 20210204 Date Completed: 20210723 Latest Revision: 20230919
Update Code:
20240105
PubMed Central ID:
PMC7847671
DOI:
10.7150/thno.52190
PMID:
33537093
Czasopismo naukowe
Background: Colorectal cancer (CRC) and the associated metastatic lesions are reported to be hypoxic. Hypoxia is a common feature in the tumor microenvironment and a potent stimulant of CRC. We have identified a regulatory role of Nur77 on Akt activation to enhance β-catenin signaling essential for CRC progression under hypoxic conditions. Methods: The functional role of Nur77 in hypoxia-induced EMT was examined by scattering assays to monitor the morphologies of CRC cell lines under 1% O 2 . Sphere formation assays were performed to investigate whether Nur77 induced cancer stem cell-like properties in hypoxic CRC cells. The expression of various epithelial-to-mesenchymal transition (EMT) and stemness markers was analyzed by qPCR and Western blotting. Finally, Nur77 function and signaling in vivo was ascertained in subcutaneous tumor xenograft or liver metastasis model in nude mice using CRC cells stably transfected with appropriate constructs. Results: Herein, we show, for the first time, that Nur77 is a novel regulator of microRNA biogenesis that may underlie its significant tumor-promoting activities in CRC cells under hypoxia. Mechanistically, Nur77 interacted with the tumor suppressor protein p63, leading to the inhibition of p63-dependent transcription of Dicer, an important miRNA processor and subsequent decrease in the biogenesis of let-7i-5p which targeted the 3'UTR of p110α mRNA and regulated its stability. Knockdown of Nur77 or overexpression of let-7i-5p inhibited the tumor metastasis in vivo . Conclusion: Our data uncovered a novel mechanistic link connecting Nur77, Akt, and invasive properties of CRC in the hypoxic microenvironment.
Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
(© The author(s).)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies